Skip to main content
. 2022 Sep 13;12:958869. doi: 10.3389/fonc.2022.958869

Table 2.

The type of immune checkpoint inhibitors(ICIs).

Drug PL group n (%) PR group n (%)
Camrelizumab 11 (34.38) 15 (51.72)
Pembrolizumab 1 (3.13) 0
Nivolumab 1 (3.13) 0
Sintilimab 12 (37.5) 7 (24.14)
Toripalimab 7 (21.88) 5 (17.24)
Tislelizumab 0 2 (6.90)